Following this evidence, the 2019 European Society of Cardiology (ESC) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases, advise the use of GLP1-RAs in class I DM2 patients at high CV risk to reduce CV [126]. This evidence concerns the gene GLP1R and diabetes mellitus.